The active compound curcumin is isolated from the spice turmeric. Curcumin, curcuminoids and their synthetic analogs have been shown to inhibit the progression of cancer in animal models. In colon and skin carcinogenesis the genetic changes engross different genes, but curcumin is effective in preventing carcinogenesis in both organs. A needful elucidation for this result is that analogues of curcumin can inhibit angiogenesis. The synthetic analog of Curcumin, 1,5 bis (3,5 dimethoxy phenyl) 1,4 pentadiene -3 one (BDMP) was tested for its capacity to inhibit the proliferation of primary endothelial cells in the presence and absence of the basic fibroblast growth factor (bFGF) and its ability to inhibit proliferation of an immortalized endothelial cell line. BDMP and other analogs of curcumin such as bis (3,4 dimethoxyphenyl) 1,3 propanedione (BDMPP), bis (2,4 dimethoxyphenyl) 1,3 propanedione (DMPP), and bis (3,3 dinitrophenyl) 2-bromo 1,3 propanedione (BDNP) were subsequently tested for their ability to inhibit bFGF-induced corneal neovascularization in the mouse cornea. Ultimately, BDMP was evaluated for its ability to inhibit phorbol esterstimulated vascular endothelial growth factor (VEGF) mRNA production. BDMP effectively inhibited endothelial cell proliferation in a dose dependent manner. BDMP, BDMPP, DMPP and BDNP have shown significant inhibition of bFGF mediated corneal neovascularization in the mouse. BDMP had no effect on phorbol ester stimulated VEGF production. Results of these investigations show that BDMP has direct antiangiogenic activity in vitro and in vivo. Carcinogenesis inhibiting activity of the BDMP in skin and colon may be mediated in part through angiogenesis inhibition. 
INTRODUCTION
Spice turmeric is a foremost constituent of the diet of the Indian subcontinent. A carotenoid pigment curcumin purified from the rhizome of curcuma longa, source of turmeric (Ammon and Wahl, 1991, Stoner and Mukhtar, 1995) . Mice treated with skin and c olon carcinogens were shown decreased size of tumors on treatment with curcumin compared to control mice (Huang et al., 1994 , Rao et al., 1995 , Conney et al., 1991 , Huang et al., 1995 , Huang et al., 1992 . Inhibition of several signal transduction pathways has been verified by curcumin, including those involving arachidonic acid metabolisms, protein kinase C, phospholipase A 2 bioactivity, the transcription factor NF-kB, antioxidant activity, and epidermal growth factor (EGF) receptor autophosphorylation (Lu et al., 1994 , Singh and aggarwal,1995 , Huang et al.,1991 , . Korutal et al., 1995 , Rao et al., 1993 In westernized nations skin and colon cancers are major public health problems. 20% of colon carcinoma in the United States due to hereditary colon cancer. Colon carcinogenesis in human disease and transgenic mice is the contribution of some genes (Dietrich et al., 1993 , Su et al., 1992 . These syndromes are usually autosomal dominant and they include ancestral adenomatous polyposis and non-polyposis syndromes.
In mice phospholipase A 2 expression has been verified to be a co-factor in genetically vulnerable mice. (Macphee et al 1995 ) In addition, deletion of the cyclooxygenase2 gene in colon carcinomaprone Apc mice results in suppression of intestinal polyposis (Oshima et al., 1996) . Loss of P 53 and activation of ras oncogenes appear later in tumor progression (Hinds et al., 1990 , Redston et al.1995 . Human skin cancers comprise the most general form of human neoplasia and are growing in frequency, principally as a result of sun exposure. In compare to colon carcinoma mutations of the p53 gene are felt to arise early in ultraviolet induced cutaneous carcinogenesis. Curcumin and its analogues have caring effects against skin and colon cancer, but the genes concerned in tumor development of skin and colon cancer differ, we hypothesized that the anti tumor effects of the BDMP may be due in part to angiogenesis embarrassment. At this point we reveal that BDMP inhibits basic fibroblast growth factor (bFGF) induced proliferation of endothelial cells in vitro and angiogenesis in vivo. In addition tested the effect of BDMPP, DMPP and BDNP on in vivo angiogenesis. Our results specify that inhibition of angiogenesis may trigger in part the antitumor activity of BDMP in vivo.
MATERIALS AND METHODS
Curcumin analogs BDMP, BDMPP, DMPP, BDNP were commercially purchased from Sigma (USA), Dulbecco's modified Eagle's medium from Hi-media Mumbai (India), 12-Otetradecanoyl phorbol-13-acetate, VEGF, Basic fibroblast growth factor were from (Sigma Aldrich, USA), sucralfate from Bukh Meditec Vaerlose, (Denmark). HaCat keratinocytes cell line purchased from NCCS (Pune India). All other reagents used were of analytical grade.
Animals: Swiss Wister albino male rats weighing 160-200 gm were obtained from Central Animal House facility, Department of Studies in Zoology, University of Mysore, Karnataka, India. Food was given ad libitum before starvation. Animal experiments were approved by the central animals house department of studies in zoology; the animal care and handling were conducted in accordance with CPCSEA office and ophthalmology guidelines University of Mysore division Mysore -India.
Endothelial proliferation assays:
Bovine capillary endothelial cells were isolated according to the method of Folkman et al (1979) and were plated at a concentration of 10,000 cells/well in gelatinized 24-well dishes. The primary endothelial cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% bovine serum and grown at 37 0 C in 10 % CO 2. Twenty-four hours after plating, cells were treated with BDMP in the presence or absence of bFGF. After 72 hours of treatment, cells were counted using a coulter counter. Cells counts for each condition were repeated in triplicate and in the presence or absence on 1 ng /ml bFGF. Similarly, MS1 (ATCC CCRL 2279) endothelial cells, which are a SV 40 large T antigen immortalized murine endothelial cell line were also plated at a concentration of 10,000 cells / well in nongelatinized 24-well dishes. MS1 cells not require endothelial mitogens for growth and were cultured in DMEM supplemented with 5% fetal calf serum. Cells were counted after 72 -hr exposure t o BDMP with the same method used for the bovine capillary endothelial cells.
Evaluation of b FGF induced corneal neovascularization by curcumin analogues:
Pellets were prepared according to a modification of the method of Kenyon et al., 1996 . An aqueous solution of 80 ng of basic fibroblast growth factor was evaporated to dryness under reduced pressure in the presence of 10 mg of sucralfate. Ten micro liters of 12 % hydron and 10 mg of BDMP or BDMPP, DMPP, BDNP were then added, and the homogenous mixture was deposited on to a sterile 15x15 mm 3-300/50 nylon mesh and air dried. Once the mixture was dry, the mesh was manually dissociated to yield 225 pellets. Each pellet contained 80 ng of b FGF and 44 µg of BDMP, BDMPP, DMPP and BDNP. Pellets prepared in the absence of b FGF were not used in this study. The approximate pore size was 0.4x0.4 mm. Both sides of the mesh were covered with a thin layer of hydron. Male Swiss Wistar rats were anesthetized with methoxyflurane prior to implantation of pellets and with 0.5% proparacaine. A central, intrastromal linear keratotomy was performed with a surgical blade, and a lamellar micropocket was prepared. The pellet was advanced to the end of the pocket. Erythromycin ointment was placed on the operated eye to prevent infection. Eyes were examined by slit lamp on day 3 -6 after implantation under general anesthesia. Corneal angiogenesis was assayed through two measurements. The first measurement, vessel length, is the length of the vessels from the corneal limbus as it grows towards the bFGF pellet. A clock hour is a measurement of neovascularized area of the cornea. The cornea is viewed as a circle that can be divided as a clock, with a maximum of 12 hrs. Thus a measurement of 3 clock hours implies that one quarter of the cornea is vascularized. This system of measurement was established by Kenyon et al (1996) .
RNAse protection for VEGF:
HaCat keratinocytes (Boukamp et al., 1998) were grown in (DMEM) supplemented with 55 FCS in 25 cm 2 flasks. One hour prior to stimulation with 12-Otetradecanoyl phorbol-13-acetate (TPA), cells were switched to serum less media supplemented with 10 µM DMP or an equal quantity of ethanol (final concentration 0.1%). TPA was added to a final concentration of 5ng/ml and incubated for 3 hr at 37 o C. Cells were harvested and RNA extracted with guanidinium thiocyanate/phenol.A plasmid containing the coding region of human vascular endothelial growth factor (VEGF) 121 used to generate P 32 -labeled antisense riboprobe as per manufacturer protocols (Ambion, Austin, TX). RNAse protection assays were performed according to the method of Hod (1992) Protected fragments were separated on gels of 5% acrylamide, 8Murea, 1X Tris-borate buffer, and quantified with a phosphor imager. An 18 S riboprobe was included in each sample to normalize for variations in loading and recovery of RNA.
Phase II Enzyme Induction: The ability of curcumin derivatives to induce phase II activities was measured by assaying quinone reductase [NAD (P) H :( quinone -acceptor) oxidoreductase, EC 1.6.99.2] in murine Hepaclc7 cells. Serial dilutions of BDMP, BDMPP, DMPP, and BDNP were added, and the concentration of compound required to double the specific activity (CD) was calculated according to the method of Prochaska et al., (1992) .
Statistics
Significant differences between two groups were determined using an unpaired, two tailed student's t-test. Results are expressed as the mean ± standard error of the mean.
RESULTS
Inhibitory effect of BDMP on Endothelial proliferation in the presence or absence of bFGF: Endothelial cells are stimulated to proliferate in the presence of 1ng/ml bFGF. BDMP was added in concentration ranging from 0.5-10 µM to primary endothelial cells. A steep decrease in cell number was seen at 10 µM. No evidence of cytotoxicity was observed, and the number of cells at the end of was not significantly less than the number of cells originally plated. This decrease was observed in either the presence or absence of bFGF (Fig 1) . In addition, BDMP was able to inhibit the growth of endothelial cells immortalized by SV40 large T antigen, with a similar dose response as seen with primary endothelial cells.
BDMP inhibit b FGF-induced Neovascularization in the m ouse cornea: The capacity of BDMP to inhibit b FGF -induced corneal neovascularization in vivo was studied. Pellets were prepared containing 80 ng of b FGF and BDMP or a control aromatic ketone, tetraphenylcyclopentadienone (TPCPD). TPCPD was added to rule out the possibility that the inhibition of neovascularization due to BDMP was not secondary to dilution. There was no difference in neovascularization in mice containing b FGF pellets in the presence or absence of TPCPD. Neovascularization was assessed by slit lamp at 5 days after implantation, and the corneas were photographed. Both the vessel length and clock hours were significantly reduced in the presence of BDMP (Fig2).
Saturated Analogs of Curcumin Inhibit b FGFInduced Neovascularization in the Mouse cornea: analogs of curcumin were assayed for their ability to inhibit bFGF induced corneal neovascularization as described above. All analogs showed inhibitory activity, with BDMPP showing the greatest activity on both clock hours and vessel length, BDNP having the least effect on clock hours, and DMPP having the least effect on vessel length (Fig3). All of the curcumin derivatives showed significant inhibition of bFGF mediated neovascularization compared with control pellets. Effect of Curcumin Derivatives on Induction of phase II enzyme Induction: To determine whether the antiangiogenic activities of the curcumin derivatives correlated with the ability to induce quinone reductase activity. The CD (concentration to double the specific activity) value for BDMP was 6.3 µM, 7.0 µM for BDMPP and 10.0 µM for DMPP. These CD values are approximately equal, but they differ significantly from that of tetrahydrocurcumin. Tetrahydrocurcumin, the curcumin derivative with the least anti tumor activity, caused a 1.2 fold induction of quinone reductase activity at 25µM. However, TPCPD, which is an unsaturated aromatic ketone with no anti-angiogenic activity, had a CD value of 4.8 µM. Thus anti-angiogenic activity does not correlate with phase II activity. Effect of BDMP on VEGF production by transformed keratinocytes: Ha Cat cells are derived from spontaneously transformed human keratinocytes (Boukamp et al., 1988) . In order to determine whether BDMP could inhibit production of angiogenesis factors by relevant tumor cells as well as directly inhibit endothelial function, we treated Ha Cat cells with tetradecanoylphorbol ester (TPA) in the presence or absence of BDMP and assayed expression of VEGF mRNA. TPA caused a 2.5-fold increase in VEGF mRNA, which was not inhibited by BDMP (Fig4) . Thus the primary anti-angiogenic effect of BDMP is directly on endothelium, rather than inhibition of production of VEGF, an important angiogenic factor. 
DISCUSSION
Curcumin is a harmless compound with wellknown chemo preventive activity in areas of direct contact, such as the gastrointestinal tract and skin (Huang et al., 1994 , Rao et al., 1995 , Conney et al., 1991 , Huang et al., 1995 , Huang et al., 1992 .The reasons for its effectiveness as a chemo preventive agent are not fully stated. Curcumin has been shown to have several activities that may affect tumorigenesis in vivo. Earliest, curcumin has been shown to inhibit tumor beginning by the carcinogens benzopyrene and 7.12, -dimethylbenzanthracene (DMBA), as well as tumor beginning induced by phorbol esters (Huang et al., 1995 , Huang et al., 1992 , Rao et al., 1993 . Curcumin has also been shown to inhibit phorbol ester induced ornithine decarboxylase, a marker of cellular proliferation and tumorigenesis, in mouse skin. In addition, curcumin has an inhibitory effect on expression of c-fos and c-jun, oncogenes that form the transcription factor AP-1. (Lu et al., 1994 , Huang et al., 1991 . Moreover these pathways influence tumor cell proliferation in vivo, and curcumin may have a dual effect on inhibiting both tumor growth in vivo through inhibiting tumor progression, as well as inhibiting angiogenesis in tumors that have already undergone the angiogenic switch.
The corneal neovascularization assay, which measure vessel length and density in response to a bFGF pellet placed in the normally avascular cornea, has confirmed useful in the characterization of multiple angiogenesis inhibitors (Kenyon et al., 1996) Potent angiogenic factor is basic fibroblast growth factor (bFGF). This aspect has been shown to be an effective stimulus for both endothelial proliferation and migration. The action of b FGF on endothelial cells may be due in part though stimulation of protein kinase C (Kent et al., 1995) .Administration of BDMP or BDMPP, DMPP, BDNP within the pellet resulted in powerful inhibition of bFGF-induced corneal neovascularization. This inhibition was not due to dilution of bFGF, as administration of a structurally related inactive compound, tetraphenylcyclopentadienone (TPCPD), has no effect on bFGFinduced corneal neovascularization.
In the presence or absence of bFGF, BDMP had a potent antiproliferative effect on the endothelial cells, with a steep curve occurring between 5 and 10µM, and this inhibition could not be overcome by the immortalizing ability of SV 40 large T antigen.
According to earlier reports, curcumin, demethoxycurcumin, bis-demethoxycurcumin were able to inhibit phorbol ester-stimulated induction of ornithine decarboxylase and promotion of mouse skin initiated with 7, 12-dimethylbenzanthracene (DMBA) (Huang et al., 1995) .These derivatives also inhibited phorbol mediated ester-mediated transformation of JB6 cells (Lu et al., 1994) Synthetic saturated and unsaturated analogues of curcumin were placed into corneal pellet and assayed for their angiogenesis inhibition. BDMP, BDMPP, DMPP, BDNP were all active in inhibiting bFGF induced neovascularization, but to unreliable degrees. BDMP, BDMPP, DMPP are to a great extent chemo preventive agent than BDNP, although all of the derivatives have antiangiogenic activity. This may be due to other activities of BDMP, such as the ability to induce phase II detoxifying enzymes, which may inhibit further tumor promotion. Unsaturated derivative BDMP has potencies in induction of phase II enzymes, where as the fully saturated BDNP has slight ability to induce phase II enzymes.
Two types of angiogenesis inhibitors have been classified such as direct angiogenesis inhibitors, which are relatively specific for endothelial cells and have little effect on tumor cells . These comprise soluble VEGF receptor antagonists and angiostatin (Kim et al., 1993 , O'Reilly et al., 1994 . Indirect inhibitors may not have direct effects on endothelial cells but may down regulate the making of an angiogenesis stimulator, such as VEGF. , Gess et al., 1996 . VEGF has been shown to be up regulated during chemically induced skin carcinogenesis; this is likely due to activation of oncogenes, such as Hras , Larcher et al., 1996 , Kohl et al., 1995 Indirect inhibitors of angiogenesis comprise inhibitors of ras mediated signal transduction, such as farnesyltransferase inhibitors (Kohl et al., 1995) The antagonism of bFGF-mediated corneal neovascularization by BDMP and BBMP, BDMPP, DMPP, BDNP propose that BDMP is a direct inhibitor of angiogenesis.
Anticancer agents are diverse group of compounds with various activities. We confirm that BDMP, another chemopreventive agent, is able to inhibiting bFGF-mediated angiogenesis in vivo. The exact mechanism of how chemopreventive agents actually prevent neoplasia is not fully understood. Angiogenesis inhibition may trigger in part the valuable activity of cancer preventive agents.
